STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213 · ADARx Pharmaceuticals, Inc.
Primary completion dateRecorded edit
− Previous value
2027-06-30
+ Updated value
2027-11-30
ADRX
ADARx Pharmaceuticals, Inc.
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
5Trials in this database
11Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| STOP-HAE: A Phase 3 Study of ADX-324 in HAENCT06960213 | ADARx Pharmaceuticals, Inc. | Phase 3 | Recruiting | 2027-11-30Estimated |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseNCT06989359 | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | 2028-12-31Estimated |
| Phase 2 Study of ADX-038 in Participants With Geographic AtrophyNCT06990269 | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | 2030-02-28Estimated |
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)NCT07428499 | ADARx Pharmaceuticals, Inc. | Phase 3 | Recruiting | 2030-06-30Estimated |
| Chinese Adults With Kidney DiseaseNCT07522099 | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | 2028-07-10Estimated |
Latest recorded trial changes
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499 · ADARx Pharmaceuticals, Inc.
Recruitment statusRecorded edit
− Previous value
Not yet recruiting
+ Updated value
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359 · ADARx Pharmaceuticals, Inc.
Primary completion dateRecorded edit
− Previous value
2027-07
+ Updated value
2028-12-31
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269 · ADARx Pharmaceuticals, Inc.
Primary completion dateRecorded edit
− Previous value
2027-09-30
+ Updated value
2030-02-28
Chinese Adults With Kidney Disease
NCT07522099 · ADARx Pharmaceuticals, Inc.
Recruitment statusRecorded edit
− Previous value
Not yet recruiting
+ Updated value
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359 · ADARx Pharmaceuticals, Inc.
Recruitment statusRecorded edit
− Previous value
Not yet recruiting
+ Updated value
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359 · ADARx Pharmaceuticals, Inc.
Enrollment · participant countRecorded edit
− Previous value
count: 30; type: ESTIMATED
+ Updated value
count: 45; type: ESTIMATED
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269 · ADARx Pharmaceuticals, Inc.
Recruitment statusRecorded edit
− Previous value
Not yet recruiting
+ Updated value
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269 · ADARx Pharmaceuticals, Inc.
Primary completion dateRecorded edit
− Previous value
2027-09
+ Updated value
2027-09-30
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213 · ADARx Pharmaceuticals, Inc.
Primary completion dateRecorded edit
− Previous value
2026-12-31
+ Updated value
2027-06-30
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213 · ADARx Pharmaceuticals, Inc.
Primary outcomes · main study measuresText edit · unverified significance
− Previous value
measure: Efficacy of ADX-324 in preventing investigator-confirmed HAE attacks
+ Updated value
measure: Efficacy of ADX-324 in preventing HAE attacks
Check registry source · The saved outcome text may be shortened. Check the source for full wording.